Streetbeat News

NLTX

Neoleukin Therapeutics Inc

Employees

Industry

Pharmaceutical Preparation Manufacturing

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Neoleukin Therapeutics has announced a 1-for-4 reverse stock split, set to take effect at 12:02 a.m. Eastern Time on December 18, 2023. This action is typically taken by companies aiming to boost their stock price by reducing the number of shares outstanding, which may help them meet exchange listing requirements or appear more financially stable.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 7:02 am

In Thursday's pre-market session, several health care stocks experienced significant movement. Dyadic International, MAIA Biotechnology, KORU Medical Systems, Comera Life Sciences, Nuwellis, and Xilio Therapeutics saw increases in their share prices, while MaxCyte, SeaStar Medical Holding, Owlet, Nanobiotix, Innate Pharma, and Neoleukin Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

October 05, 2023 | 1:10 pm

Orchard Therapeutics shares rose by 95.5% in pre-market trading after the company announced a deal to be acquired by Kyowa Kirin Co., Ltd. for a total value of about $477.6 million. Other pre-market gainers include Meiwu Technology, Molekule Group, Femasys, NKGen Biotech, Grom Social Enterprises, Better Choice Company, Momentus, China SXT Pharmaceuticals, and Tenaya Therapeutics. Pre-market losers include Cambium Networks, SIGNA Sports United, MaxCyte, Neoleukin Therapeutics, Safety Shot, Benson Hill, Inspirato, Accolade, and SeaStar Medical Holding Corporation.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 12:15 pm

Neoleukin Therapeutics has announced a 1-for-5 reverse stock split, which will become effective at 12:01 a.m. Eastern time on September 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 12:03 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. TRACON Pharma, Alpha Tau Medical, Avalo Therapeutics, Neoleukin Therapeutics, GRI Bio, and Assure Hldgs saw increases, while Athersys, Incannex Healthcare, Bone Biologics, Renovaro Biosciences, Cingulate, and VolitionRX experienced decreases. Q2 earnings reports were recently released for several of these companies.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 9:32 pm

Neoleukin Therapeutics Inc (NASDAQ:NLTX) is set to merge with privately-held Neurogene Inc in an all-stock transaction. The combined company will focus on advancing Neurogene's pipeline of genetic medicines and will operate under the name Neurogene Inc, trading under the ticker symbol 'NGNE'. The merger is expected to close in Q4 2023, with pre-merger Neoleukin stockholders owning approximately 16% of the combined company. NLTX shares are down 6.19% in premarket trading.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:26 pm

Neurogene and Neoleukin Therapeutics have entered into a definitive merger agreement. The combined company will operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol 'NGNE'. Neoleukin will issue shares to pre-merger Neurogene stockholders in exchange for the cancellation of shares of Neurogene, making Neurogene a wholly owned subsidiary of Neoleukin.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:32 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.